Ongoing Clinical Trials for Optic Glioma
Currently, there is 1 ongoing clinical trial for optic glioma, a type of brain tumor affecting the optic nerves and vision. This trial is investigating an innovative eye drop treatment containing nerve growth factor for children and young adults with this condition. (Also known as: Optic pathway glioma, OPG)
Clinical trial locations
Study on the Safety and Effectiveness of Nerve Growth Factor CHF6467 for Children and Young Adults with Optic Pathway Glioma
This clinical trial is being conducted in Italy and focuses on testing a new treatment approach for children and young adults affected by optic pathway glioma. The study investigates whether eye drops containing a substance called nerve growth factor (known as CHF6467) can help improve vision problems caused by this type of brain tumor.
Who can participate:
- Children and young adults between 3 and 40 years of age
- Individuals with a confirmed diagnosis of optic pathway glioma
- The condition must be stable, as shown by two brain MRI scans performed at least six months before joining the study
- Participants may or may not have type 1 neurofibromatosis, a genetic condition sometimes associated with this type of tumor
Who cannot participate:
- Patients without a confirmed diagnosis of optic pathway glioma
- Those outside the specified age range
- Individuals unable to use eye drops
- Patients with other medical conditions that might interfere with the study
- Those unable to follow study procedures or attend required visits
What the trial aims to achieve:
The main goal of this study is to evaluate whether CHF6467 eye drops are safe and effective in improving visual function in people with optic pathway glioma. The trial will monitor how well the treatment works and whether it causes any side effects. Participants will receive multiple doses of the eye drops over time, with some receiving the active medication and others receiving a placebo (an inactive substance that looks like the medication but contains no active ingredient).
The study involves regular assessments of visual function using specialized tests, including kinetic perimetry, which measures the field of view and visual angles. Regular follow-up visits will monitor any changes in vision and ensure the treatment remains safe throughout the trial period. The study is expected to conclude by May 2026.
Investigational drug:
The treatment being tested is CHF6467, an eye drop formulation containing Recombinant Nerve Growth Factor. This medication is designed to potentially support nerve health and function in the visual pathways affected by the tumor. By using nerve growth factor therapy, researchers hope to find a new way to help manage vision problems in people with this condition.
Summary
Currently, only one clinical trial is actively recruiting patients with optic glioma. This trial, taking place in Italy, represents an innovative approach to treating vision problems associated with this condition through the use of eye drops rather than traditional treatments. The focus on nerve growth factor therapy offers a new avenue of research that may benefit children and young adults affected by this type of brain tumor. The trial’s completion in 2026 will provide important information about whether this treatment approach can improve visual outcomes for patients with optic pathway glioma.
